Long-Term Effects of Semaglutide on Body Composition and Performance in Running

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight-loss effects in people with obesity and/or type 2 diabetes, but its impact on exercise performance among lean, fit athletes remains unknown. This randomized placebo-controlled parallel intervention study aims to investigate the long-term effects of semaglutide on body composition, muscle mass, volume and function, running economy, and performance as well as on hormonal markers in well-trained male and female runners.
Epistemonikos ID: b1f042f8898370a8516faf054b12494adbfdca71
First added on: Oct 16, 2026